Circulating Tumour DNA (ctDNA) as a Pharmacodynamic Biomarker in Tigilanol Tiglate (EBC-46) Clinical Trials

Circulating tumour DNA (ctDNA) — short fragments of cell-free DNA shed by tumour cells into the bloodstream — has rapidly become one of the most informative tools in clinical oncology trials. For an intralesional therapy such as tigilanol tiglate (EBC-46), where conventional imaging endpoints can be confounded by post-injection inflammation, ctDNA offers a complementary readout that maps onto biological response rather than gross volume change.

Why ctDNA Matters in Intralesional Trials

Tigilanol tiglate produces a rapid, localised tumour-necrosis response that typically precedes any decrease in lesion size on cross-sectional imaging. As we have discussed previously in our review of RECIST response criteria in tigilanol tiglate trials, the early period after treatment can show transient swelling, infiltration of immune cells, and oedema — all of which can make volume-based response classification unreliable in the first weeks. ctDNA, in principle, falls in real time as tumour-cell turnover declines, providing an orthogonal pharmacodynamic readout.

The Underlying Technology

Modern ctDNA assays use targeted next-generation sequencing or droplet digital PCR to detect tumour-specific somatic mutations, copy-number variants, or methylation signatures in plasma cell-free DNA. Two assay philosophies dominate: tumour-informed assays (a panel customised from a baseline tumour biopsy) and tumour-naïve assays (a fixed panel of recurrent mutations). The technology base has been reviewed in journals including the New England Journal of Medicine and the Nature Reviews Clinical Oncology comprehensive reviews of liquid biopsy applications.

What Trials Have Used ctDNA in Tigilanol Tiglate Studies

Published clinical data on tigilanol tiglate, summarised by QBiotics Group, has historically focused on local response and durable disease control. Independent oncology investigators exploring tigilanol tiglate's biological effects increasingly include exploratory ctDNA collection at screening, day 1, day 7, day 28, and at follow-up time points. These data are not yet pooled in published Phase II or III reports, but the practice is consistent with how the broader oncology community is treating any intratumoral agent in 2026.

Three Time-Resolved Questions

ctDNA can address three distinct clinical questions in the tigilanol tiglate setting. First, does ctDNA drop within hours-to-days of injection, mirroring the rapid necrotic response observed histologically? Second, does ctDNA-defined molecular response correlate with downstream RECIST response, and does it predict the durable responses described in published follow-up? Third, can serial ctDNA monitoring detect recurrence earlier than imaging — a use case that has driven adoption in colorectal, breast, and melanoma adjuvant settings.

Methodological Caveats

Several caveats apply specifically to intralesional therapy. The immediate post-injection period may transiently raise ctDNA as necrosing tumour releases fragmented DNA. Investigators must distinguish this from clearance signal — typically by sampling at multiple early time points. Tumour shed rate varies substantially by histology (low in indolent disease, high in aggressive tumours), and assay limits of detection vary between platforms. As a result, single ctDNA values are less informative than trajectories.

Connection to the Broader Biomarker Programme

ctDNA is one of several biomarker modalities being explored alongside tigilanol tiglate, complementing imaging endpoints (covered in our piece on MRI as a response biomarker), inflammatory serum markers, and tumour biopsy histology. None of these is a substitute for clinical endpoints such as overall survival or quality of life, but they accelerate decision-making in early-phase trial design and adaptive enrolment.

Relevance for the Supplement Category

The ctDNA literature described here applies exclusively to pharmaceutical-grade tigilanol tiglate administered by injection in oncology trials. Oral blushwood berry extract dietary supplements — such as those produced under GMP conditions by brands including Blushwood Health — are not the subject of these studies and are not intended to diagnose, treat, cure or prevent any disease. The trial literature is presented for scientific context, not as evidence of supplement effect.

Citations

1. Wan, Massie, Garcia-Corbacho et al., "Liquid biopsies come of age", N Engl J Med review.

2. Pascual et al., Nature Reviews Clinical Oncology — ctDNA in clinical practice, 2022.

3. QBiotics Group — Tigilanol Tiglate clinical programme.

Related Articles

Serum inflammatory biomarkers in EBC-46 trials • Surrogate endpoints and biomarkers in tigilanol tiglate trials